Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Published byΉράκλειτος Αλεξάκης Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk."— Presentation transcript:

1 (A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Safety outcome: risk of minor bleeding between TAPT versus DAPT. (C) Safety outcome: risk of any bleeding between TAPT versus DAPT. (D) Safety outcome: risk of drug discontinuation due to adverse effects between TAPT versus DAPT. Sripal Bangalore et al. Open Heart 2014;1:e000068 ©2014 by British Cardiovascular Society

Download ppt "(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk."

Similar presentations

PRODIGY Objective Study Design Primary Composite Endpoint

PRODIGY Objective Study Design Primary Composite Endpoint
Date of download: 7/8/2016 From: Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and.

Date of download: 7/8/2016 From: Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and.
Volume 55, Issue 3, Pages (May 2010)

Volume 55, Issue 3, Pages (May 2010)
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Figure 6 Differences in glycaemic control with the study drug

Figure 6 Differences in glycaemic control with the study drug
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)
Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
AF and PCI in Practice.

AF and PCI in Practice.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Similar presentations

Ads by Google